199 related articles for article (PubMed ID: 8386404)
1. Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients.
Nicol DL; MacDonald AS; Belitsky P; Lee S; Cohen AD; Bitter-Suermann H; Lowen J; Whalen A
Transplantation; 1993 Apr; 55(4):841-6. PubMed ID: 8386404
[TBL] [Abstract][Full Text] [Related]
2. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
3. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients.
Ginevri F; Losurdo G; Fontana I; Rabagliati AM; Bonatto L; Valente R; Venzano P; Nocera A; Basile GC; Valente U; Gusmano R
Transpl Int; 1998; 11 Suppl 1():S130-4. PubMed ID: 9664962
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
Dunn DL; Gillingham KJ; Kramer MA; Schmidt WJ; Erice A; Balfour HH; Gores PF; Gruessner RW; Matas AJ; Payne WD
Transplantation; 1994 Mar; 57(6):876-84. PubMed ID: 8154035
[TBL] [Abstract][Full Text] [Related]
5. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
6. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
7. Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis.
Boland GJ; Ververs C; Hené RJ; Jambroes G; Donckerwolcke RA; de Gast GC
Transpl Int; 1993 Jan; 6(1):34-8. PubMed ID: 8267694
[TBL] [Abstract][Full Text] [Related]
8. Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA; O'Kelly P; Spencer S; Hickey DP; Conlon PJ; Walshe JJ
Ren Fail; 2008; 30(2):141-6. PubMed ID: 18300112
[TBL] [Abstract][Full Text] [Related]
9. Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients.
Stratta RJ; Shaefer MS; Cushing KA; Markin RS; Wood RP; Langnas AN; Reed EC; Woods GL; Donovan JP; Pillen TJ
Transplantation; 1991 Jan; 51(1):90-7. PubMed ID: 1846254
[TBL] [Abstract][Full Text] [Related]
10. CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: a prospective study.
Rostaing L; Martinet O; Cisterne JM; Icart J; Chabannier MH; Durand D
Am J Nephrol; 1997; 17(6):489-94. PubMed ID: 9426843
[TBL] [Abstract][Full Text] [Related]
11. Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients.
Dickinson BI; Gora-Harper ML; McCraney SA; Gosland M
Ann Pharmacother; 1996 Dec; 30(12):1452-64. PubMed ID: 8968459
[TBL] [Abstract][Full Text] [Related]
12. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants.
Bailey TC; Ettinger NA; Storch GA; Trulock EP; Hanto DW; Dunagan WC; Jendrisak MD; McCullough CS; Kenzora JL; Powderly WG
Am J Med; 1993 Sep; 95(3):273-8. PubMed ID: 8396320
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
Jongsma H; Bouts AH; Cornelissen EA; Beersma MF; Cransberg K
Pediatr Transplant; 2013 Sep; 17(6):510-7. PubMed ID: 23890076
[TBL] [Abstract][Full Text] [Related]
14. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
Goral S; Ynares C; Dummer S; Helderman JH
Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
16. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir.
Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830
[TBL] [Abstract][Full Text] [Related]
17. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
19. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
20. CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.
Johnson RJ; Clatworthy MR; Birch R; Hammad A; Bradley JA
Transplantation; 2009 Jul; 88(1):77-82. PubMed ID: 19584684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
